Combination Therapy of Portal Vein Resection and Adjuvant Gemcitabine Improved Prognosis of Advanced Pancreatic Cancer

ASSOCIATION FOR ACADEMIC SURGERY AND SOCIETY OF UNIVERSITY SURGEONS—ABSTRACTS 52.2. Amphiregulin is the Key Ligand Associated with Src-Dependent EGFR Activation. V. K. Yarlagadda,5 J. A. Castellanos,1 N. S. Nagathihalli,1 Y. Beesetty,1 M. Kay Washington,2,4 R. Coffey,3,4 N. B. Merchant1,4; 1Department of Surgery, Vanderbilt University, Nashville, TN; 2 Department of Pathology, Vanderbilt University, Nashville, TN; 3Department of Cell and Developmental Biology, Vanderbilt University, Nashville, TN; 4Vanderbilt-Ingram Cancer Center, Nashville, TN; 5Meharry Medical College, Nashville, TN 52.3. Withdrawn 52.4. A Supervised Survey of MicroRNAs As Candidate Regulators of the Tumor Promoting RNA Binding Protein, HuR, in Pancreatic Cancer Cells. C. A. McIntyre,1 V. A. Talbott,1 J. M. Winter,1 G. E. Gonye,2 N. L. Simone,3 A. K. Witkiewicz,2 C. J. Yeo,1 J. R. Brody1; 1Thomas Jefferson University Hospital, Department of Surgery, Philadelphia, PA; 2Thomas Jefferson University, Department of Pathology, Philadelphia, PA; 3Thomas Jefferson University, Department of Radiation Oncology, Philadelpha, PA 52.5. The Dominant Role of Glycogen Synthase Kinase-3a in the Growth of Human Pancreatic Cancers. R. S. Sweeting,1,2 D. Bang,1 J. J. Yeh,1,2 A. S. Baldwin,1 H. J. Kim1,2; 1Lineberger Cancer Center, University of North Carolina, Chapel Hill, NC; 2UNC Department of Surgery, Division of Surgical Oncology, Chapel Hill, NC 52.6. Axl and PAxl Levels Increase in Pancreatic Cancer and Pancreatic Cancer Associated Fibroblasts Grown in Co-Culture. B. G. Wilkinson, J. E. Shea, C. L. Scaife; University of Utah-Department of Surgery, Salt Lake City, UT 52.7. MicroRNA-155 Expression in Gallbladder Carcinoma and Pancreaticobiliary Maljunction. H. Kono,1 M. Nakamura,2 T. Ohtsuka,1 M. Fujino,3 N. Ideno,1 T. Aso,1 Y. Nagayoshi,1 Y. Mori,1 S. Takahata,1 Y. Oda,3 M. Tanaka1; 1 Department of Surgery and Oncology, Kyushu University, Fukuoka, Fukuoka; 2Department of Digestive Surgery, Kawasaki Medical School, Kurashiki, Okayama; 3Department of Anatomic Pathology, Pathological Sciences, Kyushu University, Fukuoka, Fukuoka

341

52.11. Tristetraprolin (TTP) Has Tumor Suppressor Characteristics in Pancreatic Cancer Cells and Can Regulate Gemcitabine Efficacy. D. M. Pineda,1 Z. Norris,1 J. M. Winter,1 D. A. Dixon,2 A. Witkiewicz,1 C. J. Yeo,1 J. Brody1; 1 Thomas Jefferson University Hospital, Department of Surgery, Philadelphia, PA; 2University of South Carolina, Department of Biological Sciences and Cancer Research Center, Columbia, SA 52.12. Thymoquinone Promotes Pancreatic Cancer Cell Death and Reduction of Tumor Size Through Combined Inhibition of Histone Deacetylation and Induction of Histone Acetylation. D. Relles, G. Chipitsyna, Q. Gong, C. J. Yeo, H. A. Arafat; Thomas Jefferson University, Philadelphia, PA 52.13. Combination Therapy of Portal Vein Resection and Adjuvant Gemcitabine Improved Prognosis of Advanced Pancreatic Cancer. M. Nakamura,1 T. Kayashima,2 Y. Nagayoshi,2 H. Kono,2 Y. Mori,2 T. Ohtsuka,2 S. Takahata,2 K. Mizumoto,2 M. Tanaka2; 1Department of Digestive Surgery, Kawasaki Medical School, Kurashiki, Okayama; 2 Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Fukuoka 52.14. Peripancreatic Soft Tissue Involvement as a Novel Independent Predictor of Outcome for Patients with Resected Pancreatic Malignancy. A. Hamidian Jahromi,1 H. Shokouh-Amiri,1 E. Jafarimehr,1 Q. D. Chu,1 G. P. Wellman,2 R. Shi,3 G. B. Zibari1; 1Louisiana State University Health Sciences Center-Shreveport and Feist Weiller Cancer Center, Shreveport, LA; 2Willis Knighton Medical Center, Shreveport, LA; 3Louisiana State University Health Sciences Center-Shreveport and Feist Weiller Cancer Center, Shreveport, LA 52.15. Accuracy and Impact of Pet-Ct in the Diagnosis and Management of Pancreatic Lesions. G. B. Zibari,1 A. Hamidian Jahromi,1 A. Takalkar,2 Q. D. Chu,1 H. R. D’Agostino,3 H. M. Shokouh-Amiri1; 1Louisiana State University Health Sciences Center-Shreveport and Feist Weiller Cancer Center, Shreveport, LA; 2Biomedical Research Foundation, Shreveport, LA; 3Louisiana State University Health Sciences Center-Shreveport and Feist Weiller Cancer Center, Shreveport, LA

52.8. In Vivo Selection of Aptamers Targeting Pancreatic Cancer. K. L. Rialon, K. Viles, A. S. Barbas, B. Sullenger, R. R. White; Duke University Medical Center, Durham, NC

52.16. Targeting MicroRNA-196a by a Plasmid-based Antagomir for Pancreatic Cancer Therapy. L. Zhang,1 M. Jamaluddin,1 D. D. Rao,2 J. Nemunaitis,2 Q. Yao,1 C. Chen1; 1 Baylor College of Medicine, Houston, TX; 2Gradalis Inc, Carrollton, TX

52.9. 2g8, A TGFBR2 Inhibitor, Blocks Smad Dependent Signaling and Migration in Vitro in Pancreatic Cancer Cells. K. T. Ostapoff,1 B. K. Cenik,1 L. B. Rivera,1 K. D. Carroll,2 R. A. Brekken1; 1University of Texas Southwestern Medical Center, Dallas, TX; 2ImClone Systems, New York, NY

52.17. Behind the Warburg Effect: Rna-Binding Protein, HuR, Can Regulate Pancreatic Cancer Cell Metabolism. R. A. Burkhart, J. Brody, C. J. Yeo, J. M. Winter; Department of Surgery, Thomas Jefferson University Hospital, Philadelphia, PA

52.10. PG545, A Heparanase Inhibitor, Inhibits Pancreatic Cancer Tumor Cell Proliferation in Vitro and in Vivo. K. T. Ostapoff,1,2 N. Awasthi,2 R. E. Schwarz,1 R. A. Brekken1,2; 1University of Texas Southwestern Medical Center, Dallas, TX; 2University of Texas Southwestern Medical Center, Dallas, TX

52.18. Evaluation of Lysophosphatidic Acid Reprogramming in Pancreatic Ductal Adenocarcinoma. N. J. Skill,1 S. E. Samuel,1 C. M. Schmidt,1 Y. Xu,1 J. Wu,1 M. A. Maluccio1; 1 Indiana University School of Medicine-Department of Surgery, Indianapolis, IN; 2Indiana University School of Medicine, Indianapolis, IN